Dale W. Garsed

May 5, 2024 | nature.com | Nicholas W Bateman |Tamara Abulez |Dale W. Garsed |Pang-ning Teng |Clifton L. Dalgard |Mariaelena Pierobon | +5 more

Correction to: npj Precision Oncology https://doi.org/10.1038/s41698-024-00519-8, published online 13 March 2024In the original version of this article, the wrong file was inadvertently supplied for Supplementary Data 15. The original article has been corrected.

Mar 12, 2024 | nature.com | Nicholas W Bateman |Tamara Abulez |Dale W. Garsed |Pang-ning Teng |Clifton L. Dalgard |Mariaelena Pierobon | +5 more

AbstractWe performed a deep proteogenomic analysis of bulk tumor and laser microdissection enriched tumor cell populations from high-grade serous ovarian cancer (HGSOC) tissue specimens spanning a broad spectrum of purity.

Feb 27, 2023 | nature.com | Madelynne O. Willis |Allison Hunt |Ahwan Pandey |Tamara Abulez |Sian Fereday |Dale W. Garsed | +10 more

AbstractHigh-grade serous ovarian cancer (HGSC) is frequently characterized by homologous recombination (HR) DNA repair deficiency and, while most such tumors are sensitive to initial treatment, acquired resistance is common. We undertook a multiomics approach to interrogate molecular diversity in end-stage disease, using multiple autopsy samples collected from 15 women with HR-deficient HGSC.

Feb 27, 2023 | go.nature.com | Madelynne O. Willis |Allison Hunt |Ahwan Pandey |Tamara Abulez |Sian Fereday |Dale W. Garsed | +10 more

AbstractHigh-grade serous ovarian cancer (HGSC) is frequently characterized by homologous recombination (HR) DNA repair deficiency and, while most such tumors are sensitive to initial treatment, acquired resistance is common. We undertook a multiomics approach to interrogate molecular diversity in end-stage disease, using multiple autopsy samples collected from 15 women with HR-deficient HGSC.